Showing 6991-7000 of 9550 results for "".
- Breaking Business News: Allergan Acquires Bontihttps://practicaldermatology.com/news/breaking-business-news-allergan-aquires-bonti/2457610/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global
- New from Thermi: Meet the Arvati Platformhttps://practicaldermatology.com/news/new-from-thermi-meet-the-arvati-platform/2457624/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequency platform that powers a range of Thermi procedures including ThermiTight, ThermiRase, ThermiSmooth Face a
- New Skinder App May Help Med Students Spot Skin Cancerhttps://practicaldermatology.com/news/new-skinder-app-may-help-med-students-spot-skin-cancer/2457627/Skinder, a dermatologist-developed app, may help medical students learn to spot skin cancer. Skinder works like the matchmaking app Tinder. But instead of considering pictures of potential dates, swiping right if they’re attractive or left if they’re not, users consider high-r
- Psoriasis Myths, Stigmas Aboundhttps://practicaldermatology.com/news/myths-stigmas-about-psoriasis-abound/2457628/Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to multidisciplinary research from the Perelman School of Medicine at the University of Pennsylvania. The findings
- FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-ortho-derms-resubmission-of-nda-for-duobrii-lotion-for-plaque-psoriasis/2457630/The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15,
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- Wake Forest Researchers: #2 in Probiotic Advancementhttps://practicaldermatology.com/news/wake-forest-researchers-2-in-probiotic-advancements/2457638/Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the body’s ability to produce short-chain fatty acids (SCFAs). “Short-chain fa
- FDA Adds Four Tropical Diseases to Priority Review Voucher Programhttps://practicaldermatology.com/news/fda-adds-four-tropical-diseases-to-priority-review-voucher-program/2457639/The FDA announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases.
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "
- Melanoma Research Alliance Seeks Proposals, Funding Availablehttps://practicaldermatology.com/news/melanoma-research-alliance-seeks-proposals-funding-available/2457643/The Melanoma Research Alliance (MRA) is sol